Aptose Biosciences Past Earnings Performance
Past criteria checks 0/6
Aptose Biosciences's earnings have been declining at an average annual rate of -12.3%, while the Biotechs industry saw earnings growing at 12.7% annually.
Key information
-12.3%
Earnings growth rate
5.8%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | n/a |
Return on equity | n/a |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Aptose Biosciences Q2 2022 Earnings Preview
Aug 01Aptose Biosciences Continues To Drift Without Thesis-Changing Data
Jul 19Aptose Deep In The Doghouse Due To Lack Of Pipeline Progress
Feb 02Aptose: High Risk, High Reward. Watch Its Phase I Studies
Aug 05Aptose Biosciences (APTO) Presents Corporate Update at EHA 2021 - Slideshow
Jun 18Aptose Biosciences: An Assessment
Apr 27Aptose Shares Sell Off As The Market Wanted More Than Further Signs And Portents
Dec 08Aptose Shares Look Undervalued Ahead Of Value-Driving Efficacy Data
Nov 12Revenue & Expenses BreakdownBeta
How Aptose Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -51 | 16 | 37 |
30 Sep 23 | 0 | -49 | 16 | 34 |
30 Jun 23 | 0 | -48 | 16 | 33 |
31 Mar 23 | 0 | -44 | 16 | 30 |
31 Dec 22 | 0 | -42 | 15 | 28 |
30 Sep 22 | 0 | -56 | 15 | 42 |
30 Jun 22 | 0 | -58 | 15 | 43 |
31 Mar 22 | 0 | -61 | 16 | 45 |
31 Dec 21 | 0 | -65 | 19 | 46 |
30 Sep 21 | 0 | -56 | 21 | 35 |
30 Jun 21 | 0 | -58 | 23 | 35 |
31 Mar 21 | 0 | -60 | 29 | 32 |
31 Dec 20 | 0 | -55 | 26 | 29 |
30 Sep 20 | 0 | -48 | 23 | 26 |
30 Jun 20 | 0 | -42 | 20 | 23 |
31 Mar 20 | 0 | -32 | 14 | 19 |
31 Dec 19 | 0 | -26 | 10 | 17 |
30 Sep 19 | 0 | -25 | 10 | 16 |
30 Jun 19 | 0 | -24 | 9 | 15 |
31 Mar 19 | 0 | -28 | 9 | 19 |
31 Dec 18 | 0 | -29 | 10 | 19 |
30 Sep 18 | 0 | -26 | 9 | 17 |
30 Jun 18 | 0 | -23 | 9 | 14 |
31 Mar 18 | 0 | -15 | 8 | 8 |
31 Dec 17 | 0 | -12 | 6 | 6 |
30 Sep 17 | 0 | -11 | 5 | 6 |
30 Jun 17 | 0 | -12 | 6 | 6 |
31 Mar 17 | 0 | -14 | 6 | 8 |
31 Dec 16 | 0 | -14 | 6 | 8 |
30 Sep 16 | 0 | -15 | 7 | 8 |
30 Jun 16 | 0 | -14 | 7 | 7 |
31 Mar 16 | 0 | -12 | 7 | 6 |
01 Jan 16 | 0 | -12 | 8 | 5 |
30 Sep 15 | 0 | -9 | 7 | 4 |
31 Dec 14 | 0 | -12 | 8 | 4 |
31 May 14 | 0 | -10 | 6 | 2 |
28 Feb 14 | 0 | -7 | 4 | 3 |
30 Nov 13 | 0 | -6 | 3 | 3 |
31 Aug 13 | 0 | -5 | 2 | 3 |
Quality Earnings: APTO is currently unprofitable.
Growing Profit Margin: APTO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: APTO is unprofitable, and losses have increased over the past 5 years at a rate of 12.3% per year.
Accelerating Growth: Unable to compare APTO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: APTO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: APTO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.